IN2014KN02583A - - Google Patents

Info

Publication number
IN2014KN02583A
IN2014KN02583A IN2583KON2014A IN2014KN02583A IN 2014KN02583 A IN2014KN02583 A IN 2014KN02583A IN 2583KON2014 A IN2583KON2014 A IN 2583KON2014A IN 2014KN02583 A IN2014KN02583 A IN 2014KN02583A
Authority
IN
India
Prior art keywords
hpps
render
parent
hpcs
drugs
Prior art date
Application number
Other languages
English (en)
Inventor
Chongxi Yu
Lina Xu
Original Assignee
Techfields Pharma Co Ltd
Chongxi Yu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Techfields Pharma Co Ltd, Chongxi Yu filed Critical Techfields Pharma Co Ltd
Publication of IN2014KN02583A publication Critical patent/IN2014KN02583A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/625—Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G05—CONTROLLING; REGULATING
    • G05B—CONTROL OR REGULATING SYSTEMS IN GENERAL; FUNCTIONAL ELEMENTS OF SUCH SYSTEMS; MONITORING OR TESTING ARRANGEMENTS FOR SUCH SYSTEMS OR ELEMENTS
    • G05B19/00—Programme-control systems
    • G05B19/02—Programme-control systems electric
    • G05B19/18—Numerical control [NC], i.e. automatically operating machines, in particular machine tools, e.g. in a manufacturing environment, so as to execute positioning, movement or co-ordinated operations by means of programme data in numerical form
    • G05B19/409—Numerical control [NC], i.e. automatically operating machines, in particular machine tools, e.g. in a manufacturing environment, so as to execute positioning, movement or co-ordinated operations by means of programme data in numerical form characterised by using manual data input [MDI] or by using control panel, e.g. controlling functions with the panel; characterised by control panel details or by setting parameters
    • G—PHYSICS
    • G05—CONTROLLING; REGULATING
    • G05B—CONTROL OR REGULATING SYSTEMS IN GENERAL; FUNCTIONAL ELEMENTS OF SUCH SYSTEMS; MONITORING OR TESTING ARRANGEMENTS FOR SUCH SYSTEMS OR ELEMENTS
    • G05B2219/00—Program-control systems
    • G05B2219/30—Nc systems
    • G05B2219/33—Director till display
    • G05B2219/33192—Radio link, wireless

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Human Computer Interaction (AREA)
  • Manufacturing & Machinery (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Automation & Control Theory (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
IN2583KON2014 2012-01-18 2013-03-15 IN2014KN02583A (OSRAM)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210151555 2012-01-18
PCT/CN2013/072693 WO2013170655A1 (en) 2012-01-18 2013-03-15 High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions

Publications (1)

Publication Number Publication Date
IN2014KN02583A true IN2014KN02583A (OSRAM) 2015-05-08

Family

ID=49583088

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2583KON2014 IN2014KN02583A (OSRAM) 2012-01-18 2013-03-15

Country Status (17)

Country Link
US (4) US11857545B2 (OSRAM)
EP (2) EP4356912A3 (OSRAM)
JP (2) JP6445967B2 (OSRAM)
KR (6) KR20220130239A (OSRAM)
CN (4) CN116898848A (OSRAM)
AU (2) AU2013262320B2 (OSRAM)
BR (1) BR112014028643A8 (OSRAM)
CA (2) CA3189252A1 (OSRAM)
ES (1) ES2969344T3 (OSRAM)
HK (1) HK1207562A1 (OSRAM)
IN (1) IN2014KN02583A (OSRAM)
MX (1) MX378183B (OSRAM)
PL (1) PL2849738T3 (OSRAM)
RU (1) RU2683934C2 (OSRAM)
TW (1) TWI658836B (OSRAM)
WO (1) WO2013170655A1 (OSRAM)
ZA (1) ZA201407777B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3104854B1 (en) 2014-02-10 2020-04-08 Respivant Sciences GmbH Mast cell stabilizers for lung disease treatment
ES2762806T3 (es) 2014-02-10 2020-05-25 Respivant Sciences Gmbh Tratamiento utilizando estabilizadores de mastocitos para trastornos sistémicos
NO2723977T3 (OSRAM) * 2014-03-19 2018-03-10
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
CA3035528A1 (en) 2016-08-31 2018-03-08 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
CN109803724A (zh) 2016-10-07 2019-05-24 瑞思皮万特科学有限责任公司 用于治疗肺纤维化的色甘酸组合物
CN112074270A (zh) * 2018-05-10 2020-12-11 学校法人庆应义塾 前列腺癌的预防或治疗剂
SMT202300210T1 (it) 2018-09-14 2023-09-06 Enlitisa Shanghai Pharmaceutical Co Ltd Coniugati di montelukast e peptidi
WO2021175250A1 (en) * 2020-03-03 2021-09-10 Aptorum Therapeutics Limited Compounds and methods for treating diseases and/or conditions caused by coronavirus
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
CN113933401B (zh) * 2020-06-29 2023-07-21 重庆华邦制药有限公司 分离检测阿伐斯汀中间体z3中基因毒性杂质的方法
CN114409673B (zh) * 2022-01-04 2023-08-08 广东克冠达医药科技有限公司 一种吗啡喃类化合物及其制备方法与应用
AU2023207742A1 (en) * 2022-01-17 2024-08-29 Techfields Inc. Treatment of signs, symptoms and/or complications of viral, bacterial, protozoal, and/or fungal infections by high penetration prodrugs

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB100208A (en) 1915-03-24 1917-03-01 Isidore Swientoslawsk Morrison Improvements in Watch Movements.
US2694061A (en) 1949-07-07 1954-11-09 Leo Pharm Prod Ltd Method of producing aminoalcohol esters of penicillin
US2694031A (en) 1949-07-07 1954-11-09 Leo Pharm Prod Ltd Hydroiodides of amino esters of penicillin and oil composition thereof
US2694063A (en) 1949-07-07 1954-11-09 Leo Pharm Prod Ltd Quaternary ammonium addition salts of penicillin esters
US2671805A (en) 1952-07-02 1954-03-09 Searle & Co Basically substituted o-arylamino-benzamides
GB759603A (en) 1952-07-10 1956-10-24 Yvan Villax Method for the production of esters of penicillin
GB768347A (en) 1953-02-06 1957-02-13 Knud Abildgaard Sulphanilate salts of amino alcohol esters of penicillin
GB984471A (en) 1961-01-12 1965-02-24 Parke Davis & Co Anthranilic acid esters and methods for producing the same
CH399486A (fr) 1962-10-02 1965-09-30 Biosedra Lab Procédé de préparation de nouvelles salicylamides
US3365483A (en) 1963-06-05 1968-01-23 Starogardzkie Zakl Farma Process for obtaining diethylaminoethanol acetylsalicylate hydrochloride
US3420871A (en) 1964-09-01 1969-01-07 Parke Davis & Co Anthranilic acid esters
FR5342M (OSRAM) 1966-03-08 1967-09-04
DK121236B (da) 1967-07-03 1971-09-27 Gea As Analogifremgangsmåde til fremstilling af terapeutisk aktive, basisk substituerede amider af N-substituerede antranilsyrer, eller syreadditionssalte deraf.
GB1187259A (en) 1967-10-23 1970-04-08 Hexachimie New Aminoalkyl Esters of 2-Anilino-Nicotinic Acids and process for their manufacture
US3956363A (en) 1969-08-08 1976-05-11 Merck & Co., Inc. Substituted indenyl acetic acids
US3957764A (en) 1969-11-11 1976-05-18 Lovens Kemiske Fabrik Produktionsaktieselskab 6-aminopenicillanic acid derivatives
CA996929A (en) 1971-04-05 1976-09-14 Kohzi Nakano Acyloxyalkyl ester derivatives of penicillin
GB1335317A (en) 1971-06-23 1973-10-24 Leo Pharm Prod Ltd Cephalosporin esters salts thereof and methods for their pre paration
US3966923A (en) 1972-06-05 1976-06-29 Pierre Fabre S.A. Medicaments intended for the prevention and treatment of ischemic disturbances
US4006181A (en) 1972-07-27 1977-02-01 Pierre Fabre S.A. Process for the obtaining of esters of acetylsalicylic acid and amino alcohols
US3914811A (en) 1972-07-31 1975-10-28 Jonathan Francis Lightweight, compact air mattress with improved casing and inflatable members
ES428213A1 (es) 1974-07-12 1976-07-16 Andreu Sa Dr Procedimiento para la obtencion de esteres dialquilaminoal-quilicos de penicilina.
US4012508A (en) 1975-02-03 1977-03-15 Burton Verna M Topical composition and method
FR2348701A1 (fr) 1976-04-22 1977-11-18 Hexachimie Nouveau derive du p-acetamidophenol,sa preparation et son utilisation en therapeutique
US4150157A (en) 1976-06-11 1979-04-17 Beecham Group Limited Penicillin compositions
US4215120A (en) 1977-07-14 1980-07-29 Beecham Group Limited Penicillin esters and their preparation
AU518216B2 (en) 1977-09-06 1981-09-17 Hafslund Nycomed Pharma Aktiengesellschaft Thienothiazine derivatives
US4206220A (en) 1978-07-13 1980-06-03 Interx Research Corporation Prodrugs for the improved delivery of non-steroidal anti-inflammatory agents
US4244948A (en) 1979-05-07 1981-01-13 Allergan Pharmaceuticals, Inc. Medical use of esters of acetylsalicylic acid to treat acne
IN153407B (OSRAM) 1979-09-28 1984-07-14 Ciba Geigy Ag
DE3023206A1 (de) 1979-11-02 1982-01-14 Efeka Friedrich & Kaufmann GmbH & Co KG, 3000 Hannover Indometacin-ester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPS57183738A (en) 1981-05-06 1982-11-12 Yamanouchi Pharmaceut Co Ltd Aromatic carboxylic acid derivative
JPS5852291A (ja) 1981-09-22 1983-03-28 Kureha Chem Ind Co Ltd ペニシリン系抗生物質誘導体とその医薬剤
FR2542998B1 (fr) 1983-03-24 1986-01-31 Rhone Poulenc Sante Nouvelle forme transdermale du dinitrate d'isosorbide
US4640689A (en) 1983-08-18 1987-02-03 Drug Delivery Systems Inc. Transdermal drug applicator and electrodes therefor
DE3347128A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 9-halogen-(delta)(pfeil hoch)2(pfeil hoch)-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP0152379A3 (de) 1984-02-15 1986-10-29 Ciba-Geigy Ag Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
GB2157284B (en) 1984-04-11 1987-11-04 Leo Pharm Prod Ltd 6-b-halopenicillanic acid salts
GB8511988D0 (en) 1985-05-11 1985-06-19 Beecham Group Plc Compounds
US4822773A (en) 1985-06-28 1989-04-18 Merck & Co., Inc. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts
IT1213579B (it) 1986-07-03 1989-12-20 Angelo Signor Marino Nicolini Flogistica. esteri di salsalato con guaiacolo atti al trattamento di broncopneumapatie a base
ZA882957B (en) 1987-04-27 1989-12-27 Syntex Pharma Int Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal anti-inflammatory drugs
US5321020A (en) 1989-03-28 1994-06-14 Pfizer Inc. Antibacterial 2-carbapenem derivatives
JP2672363B2 (ja) 1989-03-29 1997-11-05 帝人株式会社 有機非線形光学材料
US5760261A (en) 1990-02-28 1998-06-02 Guttag; Alvin Higher fatty acid derivatives of salicylic acid and salts thereof
US5109011A (en) 1990-07-30 1992-04-28 Hoechst-Roussel Pharmaceuticals Incorporated P-acylaminophenoxycarbamates and derivatives
CA2120927A1 (en) 1991-10-16 1993-04-29 George E. Deckner Enhanced skin penetration system for improved topical delivery of drugs
HRP921157A2 (en) 1991-12-20 1994-10-31 Lohmann Therapie Syst Lts Transdermal system of applying acetilsalicilyc acid in antithrombosys therapy
US5629019A (en) 1992-02-27 1997-05-13 Alza Corporation Formulations with hydrophobic permeation enhancers
US5190953A (en) 1992-03-26 1993-03-02 A. H. Robins Company, Incorporated Heterocyclic carboxylic acid amides and esters of azabicyclic compounds as gastric prokinetic, antiemetic, anxiolytic and antiarrhythmic agents
US5300512A (en) 1992-06-24 1994-04-05 G. D. Searle & Co. Benzimidazole compounds
US5554627A (en) 1992-10-30 1996-09-10 Merck, Sharp & Dohme Ltd. Tachykinin antagonists
US5399562A (en) 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
GB9404756D0 (en) 1994-03-11 1994-04-27 Knx Limited Data output control
WO1995034813A1 (en) 1994-06-14 1995-12-21 Smithkline Beecham Corporation Resins for solid state synthesis
US5626838A (en) 1995-03-13 1997-05-06 The Procter & Gamble Company Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
AUPN531195A0 (en) 1995-09-11 1995-10-05 J.W. Broadbent Nominees Pty. Ltd. Lipid extract having anti-inflamatory activity
US5570559A (en) 1995-09-26 1996-11-05 Lewis; Thomas D. Fall arrestor
US5929086A (en) 1996-05-10 1999-07-27 Pharmacia & Upjohn Company Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases
WO1997042954A1 (en) 1996-05-10 1997-11-20 Pharmacia & Upjohn Company Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases
IT1282736B1 (it) 1996-05-21 1998-03-31 Angelini Ricerche Spa Uso di derivati del p-amminofenolo per preparare composizioni farmaceutiche utili nel trattamento di malattie neurodegenerative
KR100213465B1 (ko) 1996-11-01 1999-08-02 최좌진 케토프로펜 패취 조성물
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
DK0966277T3 (da) 1997-03-10 2006-03-27 Univ Loma Linda Med Anvendelse af R-NSAID'er til forebyggelse af Alzheimer's sygdom
US6451815B1 (en) 1997-08-14 2002-09-17 Aventis Pharmaceuticals Inc. Method of enhancing bioavailability of fexofenadine and its derivatives
US5885597A (en) 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain
SK10852000A3 (sk) 1998-01-29 2002-02-05 Bristol-Myers Squibb Company Deriváty 1,3,4-oxadiazolónu
ATE399565T1 (de) 1998-07-07 2008-07-15 Transdermal Technologies Inc Zusammensetzungen für die schnelle und nicht- irritierende transdermale verabreichung von pharmazeutika and verfahren zur formuliering davon und ihren verabreichung
US20030087962A1 (en) 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
SE9900941D0 (sv) 1998-12-23 1999-03-16 Nomet Management Serv Bv Novel retinoic acid derivatives and their use
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
US6368618B1 (en) 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
WO2001052823A2 (en) 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
DE10034802A1 (de) 2000-07-18 2002-01-31 Bayer Ag Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren
US6416772B1 (en) 2001-01-12 2002-07-09 H. Wayne Van Engelen Topical dermal anaesthetic
US6528040B1 (en) 2001-01-18 2003-03-04 Maurine Pearson EMU oil-based formulations for use as an analgesic, anesthetic and antipruritic
ITMI20010395A1 (it) 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
WO2003022270A1 (en) 2001-09-13 2003-03-20 Noven Pharmaceuticals, Inc. Transdermal administration of an enalapril ester
EP1443929A4 (en) 2001-10-16 2008-02-06 Hypnion Inc TREATMENT OF CNS DISTURBANCES WITH CNS TARGET MODULATORS
US20030143165A1 (en) 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
ITMI20021399A1 (it) 2002-06-25 2003-12-29 Nicox Sa Inibitori della cicloossigenasi 2
HK1080447B (zh) 2002-07-23 2008-10-31 Ardenia Investments, Ltd. 视黄醇衍生物、它们在治疗癌症和增强其它细胞毒性剂功效中的应用
KR102008768B1 (ko) 2002-09-06 2019-08-08 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
RU2332425C2 (ru) * 2002-09-06 2008-08-27 Инсёрт Терапьютикс, Инк. Полимеры на основе циклодекстрина для доставки терапевтических средств
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
ES2436606T3 (es) 2003-03-12 2014-01-03 Celgene Corporation Compuestos de 7-amido-isoindolilo y sus usos farmacéuticos
US7052715B2 (en) 2003-04-11 2006-05-30 All Natural Fmg, Inc. Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof
MXPA05013478A (es) 2003-06-10 2006-03-09 Pfizer Combinaciones terapeuticas.
NZ601772A (en) 2003-07-29 2012-10-26 Signature R & D Holdings Llc Amino Acid Prodrugs
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
DE10335726A1 (de) 2003-08-05 2005-03-03 Bayer Cropscience Gmbh Verwendung von Hydroxyaromaten als Safener
WO2005030331A1 (en) 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
US7186744B2 (en) 2003-11-13 2007-03-06 Allergan, Inc. Prostamides for the treatment of glaucoma and related diseases
CA2562219A1 (en) 2004-04-05 2005-10-20 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol combined to at least an nsaid
DE102004025324A1 (de) 2004-05-19 2005-12-08 Boehringer Ingelheim Vetmedica Gmbh Flüssige Zubereitung für die Veterinärmedizin, Verfahren zu deren Herstellung und deren Verwendung
TWI276687B (en) 2004-06-30 2007-03-21 Univ Nat Cheng Kung Method for kinetic resolution of alpha-substituted acids and esters thereof by using papaya lipases
JP2008120684A (ja) 2005-03-07 2008-05-29 Kumamoto Univ 抗アレルギー薬
CA2601179A1 (en) 2005-03-16 2006-09-21 Elan Pharma International Limited Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
US20060222692A1 (en) 2005-03-31 2006-10-05 Fairfield Clinical Trials Llc Method and compositions for transdermal administration of antimicrobial medications
WO2006128184A2 (en) 2005-05-20 2006-11-30 Alantos-Pharmaceuticals, Inc. Pyrimidine or triazine fused bicyclic metalloprotease inhibitors
CN100500149C (zh) * 2005-06-22 2009-06-17 晟德大药厂股份有限公司 白三烯素拮抗剂口服液组成
EP2610242A1 (en) 2006-07-09 2013-07-03 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of aspirin
WO2008044095A1 (en) 2006-10-11 2008-04-17 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of oxicams and related compounds with very high skin penetration rate
WO2008012603A1 (en) 2006-07-26 2008-01-31 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of diflunisal and related compounds with very fast skin penetration rate
DK2041068T3 (en) 2006-07-18 2017-02-27 Techfields Biochem Co Ltd POSITIVELY CHARGED, WATER SOLUBLE PRODRUGS OF IBUPROFEN WITH VERY FAST SKIN PENETRATION SPEED
CA2658712C (en) 2006-07-25 2018-10-02 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of diclofenac with very fast skin penetration rate
DK2049482T3 (en) * 2006-08-08 2016-02-01 Techfields Biochem Co Ltd Positively charged, water-soluble prodrugs of aryl and heteroaryl acetic acids with very fast skin penetration rate
US8458932B2 (en) 2006-08-11 2013-06-11 Alameda Technology, Llc Optical illusion device
CA2660814C (en) 2006-08-15 2017-07-18 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of aryl- and heteroarylpropionic acids with very fast skin penetration rate
WO2008026776A1 (en) 2006-08-31 2008-03-06 Nanocarrier Co., Ltd. Transdermal composition, transdermal pharmaceutical composition and transdermal cosmetic composition comprising polymer micelle encapsulating active ingredient
CA2661649C (en) 2006-09-03 2014-12-30 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
PL2623495T3 (pl) * 2006-09-03 2019-11-29 Techfields Biochem Co Ltd Dodatnio naładowane rozpuszczalne w wodzie proleki kwasów n-aryloantranilowych o bardzo dużej szybkości przenikania przez skórę
PL2084124T3 (pl) 2006-10-02 2014-08-29 Techfields Biochem Co Ltd Dodatnio naładowane rozpuszczalne w wodzie proleki prostaglandyn i związków pokrewnych o bardzo dużych szybkościach przenikania przez skórę
EP2077991B1 (en) 2006-10-03 2014-02-26 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of mustards and related compounds with very high skin penetration rates
CN101547898B (zh) 2006-12-10 2014-09-24 于崇曦 β-内酰胺类抗生素的透皮给药系统
HUE031307T2 (hu) * 2007-01-31 2017-07-28 Chongxi Yu 1H-imidazo[4,5-C]kinolin-4-aminok és rokon vegyületek pozitív töltésû vízoldható prodrugjai, amelyek nagyon magas bõr-penetrációs sebességekkel rendelkeznek
US7781580B2 (en) * 2007-04-23 2010-08-24 Virginia Commonwealth University Stilbene derivatives as new cancer therapeutic agents
WO2008149181A1 (en) * 2007-06-04 2008-12-11 Techfields Inc Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses
JP2011501730A (ja) * 2007-08-10 2011-01-13 ニコックス エス エイ 呼吸器系疾患を治療するためのニトロ誘導されたステロイドと気管支拡張剤との組合せ
WO2009122187A2 (en) * 2008-04-03 2009-10-08 Cipla Limited Pharmaceutical composition
MX362949B (es) * 2008-12-04 2019-02-27 Yu Chongxi Composiciones de alta penetracion y sus aplicaciones.
US8084896B2 (en) 2008-12-31 2011-12-27 Electro Scientific Industries, Inc. Monolithic stage positioning system and method
ES2845612T3 (es) * 2009-05-08 2021-07-27 Techfields Biochem Co Ltd Composiciones de profármaco de alta penetración de péptidos y compuestos relacionados con péptidos
WO2010142241A1 (en) * 2009-06-10 2010-12-16 Techfields Biochem Co., Ltd. High penetration compositions or prodrugs of antimicrobials and antimicrobial-related compounds
TWI496577B (zh) * 2010-06-10 2015-08-21 Shanghai Techfields Biochem Co Ltd 抗菌劑和抗菌劑相關化合物的高滲透性前藥組合物
EP2407161A1 (en) * 2010-07-13 2012-01-18 Sanofi An antitumoral combination comprising ombrabulin and bevacizumab

Also Published As

Publication number Publication date
CN111012914A (zh) 2020-04-17
KR20210034109A (ko) 2021-03-29
KR20200039029A (ko) 2020-04-14
KR102232625B1 (ko) 2021-03-25
US11813256B2 (en) 2023-11-14
CA2872121A1 (en) 2013-11-21
HK1208633A1 (en) 2016-03-11
EP2849738C0 (en) 2023-12-06
CN116898848A (zh) 2023-10-20
JP2019069948A (ja) 2019-05-09
AU2013262320B2 (en) 2018-02-22
BR112014028643A8 (pt) 2021-11-03
KR102443057B1 (ko) 2022-09-14
JP7235487B2 (ja) 2023-03-08
TWI658836B (zh) 2019-05-11
TW201402148A (zh) 2014-01-16
KR20240145521A (ko) 2024-10-07
JP2015516444A (ja) 2015-06-11
EP4356912A3 (en) 2024-10-30
AU2013262320A1 (en) 2014-11-13
ZA201407777B (en) 2020-01-29
KR20150020301A (ko) 2015-02-25
CA2872121C (en) 2023-02-14
EP2849738A1 (en) 2015-03-25
JP6445967B2 (ja) 2018-12-26
CN104540504A (zh) 2015-04-22
CN107929743A (zh) 2018-04-20
HK1254324A1 (zh) 2019-07-19
US20150072961A1 (en) 2015-03-12
US20240131017A1 (en) 2024-04-25
WO2013170655A1 (en) 2013-11-21
ES2969344T3 (es) 2024-05-17
EP4356912A2 (en) 2024-04-24
KR102332837B1 (ko) 2021-12-01
US20240226084A9 (en) 2024-07-11
KR20210148394A (ko) 2021-12-07
US20240115562A1 (en) 2024-04-11
MX378183B (es) 2025-03-10
KR20220130239A (ko) 2022-09-26
CN107929743B (zh) 2023-09-01
EP2849738A4 (en) 2016-03-30
BR112014028643A2 (pt) 2021-08-03
AU2018203612A1 (en) 2018-06-14
KR102309973B1 (ko) 2021-10-06
CA3189252A1 (en) 2013-11-21
MX2014013910A (es) 2015-06-04
US11857545B2 (en) 2024-01-02
PL2849738T3 (pl) 2024-05-13
HK1207562A1 (en) 2016-02-05
RU2014150779A (ru) 2016-07-10
EP2849738B1 (en) 2023-12-06
RU2683934C2 (ru) 2019-04-03
US20190142818A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
IN2014KN02583A (OSRAM)
MX386251B (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
CY1120832T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
MX379054B (es) Composiciones de alta penetracion y sus aplicaciones.
UA117103C2 (uk) Сполука, яка має активність агоніста глюкагону
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
MX395482B (es) Compuestos antiproliferativos y metodos de uso de los mismos
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
MX366035B (es) Composiciones o pro-fármacos de alta penetración de compuestos antimicrobianos o relacionados a los antimicrobianos.
HK1217092A1 (zh) 治疗性化合物及其用途
WO2016100949A3 (en) Method and compositions for dissolving or solubilizing therapeutic agents
EP2871187A4 (en) A NEW CONNECTION OR PHARMACEUTICALALLY SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS AN ACTIVE SUBSTANCE
HK1219896A1 (zh) 使用4-氨基-2-(2，6-二氧代-呱啶-3-基)-异吲哚啉-1，3-二酮治疗和控制中枢神经系统癌症的方法和组合物
NZ726132A (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
NZ726131A (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
BR112017012975A2 (pt) formulações injetáveis de paracetamol
PH12020500472A1 (en) Autotaxin inhibitor compounds
Kwon Issues in an improvement plan for doctors fee system and its policy task
IN2013MU01252A (OSRAM)
TH161822A (th) การบำบัดซีบอเรีย